132 related articles for article (PubMed ID: 37677989)
1. A novel bispecific antibody as an immunotherapeutic agent in hepatocellular carcinoma.
Liu Q; Song Q; Luo C; Wei J; Xu Y; Zhao L; Wang Y
Mol Immunol; 2023 Oct; 162():125-132. PubMed ID: 37677989
[TBL] [Abstract][Full Text] [Related]
2. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma.
Zhu AX; Gold PJ; El-Khoueiry AB; Abrams TA; Morikawa H; Ohishi N; Ohtomo T; Philip PA
Clin Cancer Res; 2013 Feb; 19(4):920-8. PubMed ID: 23362325
[TBL] [Abstract][Full Text] [Related]
3. A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC.
Du K; Li Y; Liu J; Chen W; Wei Z; Luo Y; Liu H; Qi Y; Wang F; Sui J
Mol Ther; 2021 Apr; 29(4):1572-1584. PubMed ID: 33429083
[TBL] [Abstract][Full Text] [Related]
4. Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma.
Ikeda M; Ohkawa S; Okusaka T; Mitsunaga S; Kobayashi S; Morizane C; Suzuki I; Yamamoto S; Furuse J
Cancer Sci; 2014 Apr; 105(4):455-62. PubMed ID: 24521523
[TBL] [Abstract][Full Text] [Related]
5. Combination Therapy of Hepatocellular Carcinoma by GPC3-Targeted Bispecific Antibody and Irinotecan is Potent in Suppressing Tumor Growth in Mice.
Chen X; Chen Y; Liang R; Xiang L; Li J; Zhu Y; He H; Huang L; Zuo D; Li W; Liang X; Dong S; Hu S; Ho M; Feng M
Mol Cancer Ther; 2022 Jan; 21(1):149-158. PubMed ID: 34725191
[TBL] [Abstract][Full Text] [Related]
6. Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma.
Bell MM; Gutsche NT; King AP; Baidoo KE; Kelada OJ; Choyke PL; Escorcia FE
Molecules; 2020 Dec; 26(1):. PubMed ID: 33374953
[TBL] [Abstract][Full Text] [Related]
7. A novel targeted GPC3/CD3 bispecific antibody for the treatment hepatocellular carcinoma.
Yu L; Yang X; Huang N; Lang QL; He QL; Jian-Hua W; Liang-Peng G
Cancer Biol Ther; 2020 Jul; 21(7):597-603. PubMed ID: 32240054
[TBL] [Abstract][Full Text] [Related]
8. Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma.
Ofuji K; Saito K; Yoshikawa T; Nakatsura T
J Hepatocell Carcinoma; 2014; 1():35-42. PubMed ID: 27508174
[TBL] [Abstract][Full Text] [Related]
9. Glypican-3 antibodies: a new therapeutic target for liver cancer.
Feng M; Ho M
FEBS Lett; 2014 Jan; 588(2):377-82. PubMed ID: 24140348
[TBL] [Abstract][Full Text] [Related]
10. Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization.
Nakano K; Ishiguro T; Konishi H; Tanaka M; Sugimoto M; Sugo I; Igawa T; Tsunoda H; Kinoshita Y; Habu K; Orita T; Tsuchiya M; Hattori K; Yamada-Okabe H
Anticancer Drugs; 2010 Nov; 21(10):907-16. PubMed ID: 20847643
[TBL] [Abstract][Full Text] [Related]
11. Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells.
Nakano K; Orita T; Nezu J; Yoshino T; Ohizumi I; Sugimoto M; Furugaki K; Kinoshita Y; Ishiguro T; Hamakubo T; Kodama T; Aburatani H; Yamada-Okabe H; Tsuchiya M
Biochem Biophys Res Commun; 2009 Jan; 378(2):279-84. PubMed ID: 19022220
[TBL] [Abstract][Full Text] [Related]
12. Nonviral mcDNA-mediated bispecific CAR T cells kill tumor cells in an experimental mouse model of hepatocellular carcinoma.
Wang H; Wang X; Ye X; Ju Y; Cao N; Wang S; Cai J
BMC Cancer; 2022 Jul; 22(1):814. PubMed ID: 35879685
[TBL] [Abstract][Full Text] [Related]
13. Histopathological analyses of the antitumor activity of anti-glypican-3 antibody (GC33) in human liver cancer xenograft models: The contribution of macrophages.
Takai H; Kato A; Kinoshita Y; Ishiguro T; Takai Y; Ohtani Y; Sugimoto M; Suzuki M
Cancer Biol Ther; 2009 May; 8(10):930-8. PubMed ID: 19276671
[TBL] [Abstract][Full Text] [Related]
14. Time-to-event modelling of effect of codrituzumab on overall survival in patients with hepatocellular carcinoma.
Nakamura M; Xu C; Diack C; Ohishi N; Lee RM; Iida S; Kawanishi T; Ohtomo T; Abou-Alfa GK; Chen YC
Br J Clin Pharmacol; 2018 May; 84(5):944-951. PubMed ID: 29381229
[TBL] [Abstract][Full Text] [Related]
15. 32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma.
Liu X; Gao F; Jiang L; Jia M; Ao L; Lu M; Gou L; Ho M; Jia S; Chen F; Gao W
J Transl Med; 2020 Aug; 18(1):295. PubMed ID: 32746924
[TBL] [Abstract][Full Text] [Related]
16. Glypican-3-Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma.
Fu Y; Urban DJ; Nani RR; Zhang YF; Li N; Fu H; Shah H; Gorka AP; Guha R; Chen L; Hall MD; Schnermann MJ; Ho M
Hepatology; 2019 Aug; 70(2):563-576. PubMed ID: 30353932
[TBL] [Abstract][Full Text] [Related]
17. A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity.
Wang Y; Liu J; Pan H; Xing J; Wu X; Li Q; Wang Z
J Vis Exp; 2018 Jul; (137):. PubMed ID: 30059039
[TBL] [Abstract][Full Text] [Related]
18. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.
Haruyama Y; Kataoka H
World J Gastroenterol; 2016 Jan; 22(1):275-83. PubMed ID: 26755876
[TBL] [Abstract][Full Text] [Related]
19. Far-Red Light Triggered Production of Bispecific T Cell Engagers (BiTEs) from Engineered Cells for Antitumor Application.
Zhang C; Shi Y; Wu L; Wang C; Liao N; Wang F; Zhao B; Wang Y; Liu X
ACS Synth Biol; 2022 Feb; 11(2):888-899. PubMed ID: 35113526
[TBL] [Abstract][Full Text] [Related]
20. Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate.
Waaijer SJ; Giesen D; Ishiguro T; Sano Y; Sugaya N; Schröder CP; de Vries EG; Lub-de Hooge MN
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]